Myeloma-Developing Regimens Using Genomics (MyDRUG)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Relapsed Refractory Multiple Myeloma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Eight Arms with 38 patients per armMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The study will enroll 228 patients enrolled to one of eight treatment arms. The study is open to patients relapsing with relapsed refractory multiple myeloma, who have received at least one prior but no more than 3 prior therapies exposed to both a PI and an IMiD had early relapse after initial trea...
The study will enroll 228 patients enrolled to one of eight treatment arms. The study is open to patients relapsing with relapsed refractory multiple myeloma, who have received at least one prior but no more than 3 prior therapies exposed to both a PI and an IMiD had early relapse after initial treatment. Relapse is defined as the IMWG uniform response criteria (Kumar et al, 2016). Early relapse as defined by at least one of the following: Relapse within 3 years post autologous stem cell transplantation (ASCT) on maintenance, or 18 months if unmaintained Relapse within 18 months of initial non-ASCT based therapy
Tracking Information
- NCT #
- NCT03732703
- Collaborators
- AbbVie
- Celgene Corporation
- Eli Lilly and Company
- Genentech, Inc.
- Janssen, LP
- Takeda
- GlaxoSmithKline
- Karyopharm Therapeutics Inc
- Investigators
- Principal Investigator: Hearn J Cho, M.D., Ph.D. Multiple Myeloma Research Consortium Principal Investigator: Daniel Auclair, Ph.D. Multiple Myeloma Research Consortium
Get Well Soon